SHENZHEN, China, Nov. 20, 2023 /PRNewswire/ — Temu, the e-commerce platform renowned for its exceptionally low prices, is intensifying its efforts to safeguard its reputation amid a surge in scams exploiting its rising popularity. Since its U.S. launch last September, Temu has rapidly expanded its user base, addressing underserved demand for affordable, practical merchandise. It… Continue reading Temu takes action against scam websites in effort to strengthen consumer trust
Category: Newswire
Wudang tai chi continues to wow the world
BEIJING, Nov. 20, 2023 /PRNewswire/ — This is a report from China Daily: Kung fu sequences in the 2000 movie Crouching Tiger, Hidden Dragon wowed audiences around the world by opening a window on the exotic and mysterious Wudang martial arts, and more than two decades later, fans of those ancient skills rekindled their appreciation during the World… Continue reading Wudang tai chi continues to wow the world
Le Groupe Chiesi a signé un accord de licence avec Haisco Pharmaceutical pour développer, fabriquer et commercialiser un nouvel inhibiteur réversible de la dipeptidyl peptidase 1 pour le traitement de la bronchectasie
– Le groupe Chiesi et Haisco Pharmaceutical collaboreront étroitement pour développer HSK31858, un nouvel inhibiteur réversible de la dipeptidyl peptidase 1 (DPP1) pour les maladies respiratoires. – Cet accord élargit le vaste programme de R&D de Chiesi dans le domaine de la bronchectasie, une maladie respiratoire dont les besoins médicaux ne sont pas satisfaits et pour laquelle il… Continue reading Le Groupe Chiesi a signé un accord de licence avec Haisco Pharmaceutical pour développer, fabriquer et commercialiser un nouvel inhibiteur réversible de la dipeptidyl peptidase 1 pour le traitement de la bronchectasie
WHERE SAFETY MEETS INNOVATION: FIRE SAFE BUILD INDIA DRIVES INDUSTRY TRANSFORMATION
MUMBAI, India, Nov. 20, 2023 /PRNewswire/ — FIRE SAFE BUILD INDIA , a pioneering exhibition focused on passive fire protection solutions, will be held from 1st-3rd February, 2024 at Jio World Convention Centre, Mumbai. Organised by NuernbergMesse India, the second edition of the event will bring together industry leaders, professionals, and innovators from the field… Continue reading WHERE SAFETY MEETS INNOVATION: FIRE SAFE BUILD INDIA DRIVES INDUSTRY TRANSFORMATION
Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis
Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases. This agreement expands Chiesi’s comprehensive R&D program in bronchiectasis, a respiratory disease with high unmet medical needs, for which no approved treatment is available to date. Haisco Pharmaceutical will receive an upfront payment and… Continue reading Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis
Segway-Ninebot Receives the World’s First Tick Mark Certificate for Kids e-KickScooter
LOS ANGELES, Nov. 20, 2023 /PRNewswire/ — Segway-Ninebot, a leading provider of innovative mobility solutions, is pleased to announce that its children’s electric scooter, the Ninebot e-KickScooter C2 Pro, has received the prestigious Tick Mark certification from Intertek, making it the world’s first children’s electric scooter to achieve this distinction. Intertek has helped companies around… Continue reading Segway-Ninebot Receives the World’s First Tick Mark Certificate for Kids e-KickScooter
LyondellBasell to Build Industrial-scale Advanced Recycling Plant in Germany
HOUSTON, Nov. 20, 2023 /PRNewswire/ — LyondellBasell (LYB) today announced it has made the final investment decision to build the company’s first industrial-scale catalytic advanced recycling demonstration plant at its Wesseling, Germany, site. Using LyondellBasell’s proprietary MoReTec technology, this plant will be the first commercial scale, single-train advanced recycling plant to convert post-consumer plastic waste… Continue reading LyondellBasell to Build Industrial-scale Advanced Recycling Plant in Germany
BioCatch Surpasses $100m USD ARR
BioCatch Becomes Centaur with more than 50% Growth YoY in Annual Recurring Revenue (ARR); Achieves Profitability While Scaling Operations & Global Reach Faster than any Other Behavioral-Powered Digital Fraud Prevention Vendor in History TEL AVIV, Israel and NEW YORK, Nov. 20, 2023 /PRNewswire/ — BioCatch, the global leader in digital fraud and money laundering detection… Continue reading BioCatch Surpasses $100m USD ARR
WHERE SAFETY MEETS INNOVATION: FIRE SAFE BUILD INDIA DRIVES INDUSTRY TRANSFORMATION
MUMBAI, India, Nov. 20, 2023 /PRNewswire/ — FIRE SAFE BUILD INDIA , a pioneering exhibition focused on passive fire protection solutions, will be held from 1st-3rd February, 2024 at Jio World Convention Centre, Mumbai. Organised by NuernbergMesse India, the second edition of the event will bring together industry leaders, professionals, and innovators from the field… Continue reading WHERE SAFETY MEETS INNOVATION: FIRE SAFE BUILD INDIA DRIVES INDUSTRY TRANSFORMATION
Chiesi Group hat Lizenzvereinbarung mit Haisco Pharmaceutical zur Entwicklung, Herstellung und Vermarktung eines neuartigen, reversiblen Dipeptidylpeptidase 1-Inhibitors zur Behandlung von Bronchiektasen unterzeichnet
Die Chiesi Group und Haisco Pharmaceutical werden eng zusammenarbeiten, um HSK31858 zu entwickeln, einen neuartigen, reversiblen Dipeptidylpeptidase 1 (DPP1)-Inhibitor für Atemwegserkrankungen. Mit dieser Vereinbarung erweitert Chiesi sein umfassendes Forschungs- und Entwicklungsprogramm für Bronchiektasen, eine Atemwegserkrankung mit hohem ungedeckten medizinischem Bedarf, für die es bisher keine zugelassene Behandlung gibt. Haisco Pharmaceutical erhält eine Vorabzahlung und künftige… Continue reading Chiesi Group hat Lizenzvereinbarung mit Haisco Pharmaceutical zur Entwicklung, Herstellung und Vermarktung eines neuartigen, reversiblen Dipeptidylpeptidase 1-Inhibitors zur Behandlung von Bronchiektasen unterzeichnet